Intravitreal bevacizumab (Avastin®) for diabetic retinopathy at 24-months: The 2008 Juan Verdaguer-planas lecture

Diabetic retinopathy (DR) remains the major threat to sight in the working age population. Diabetic macular edema (DME) is a manifestation of DR that produces loss of central vision. Proliferative diabetic retinopathy (PDR) is a major cause of visual loss in diabetic patients. In PDR, the growth of...

Full description

Autores:

Tipo de recurso:

Fecha de publicación:

2010

Institución:

Universidad del Rosario

Repositorio:

Repositorio EdocUR - U. Rosario

Idioma:

eng

OAI Identifier:

oai:repository.urosario.edu.co:10336/23801

Acceso en línea:

https://doi.org/10.2174/157339910793360842
https://repository.urosario.edu.co/handle/10336/23801

Palabra clave:

Bevacizumab
Angiogenesis inhibitor
Bevacizumab
Monoclonal antibody
Article
Diabetic macular edema
Diabetic retinopathy
Disease severity
Follow up
Human
Laser coagulation
Macular thickness
Priority journal
Proliferative diabetic retinopathy
Retina detachment
Treatment outcome
Visual acuity
Adult
Aged
Animal
Article
Cell proliferation
Diabetic retinopathy
Drug effect
Evaluation
Female
Intravitreal drug administration
Male
Middle aged
Optical coherence tomography
Retina macula edema
Retrospective study
Time
Adult
Aged
Angiogenesis inhibitors
Animals
Cell proliferation
Diabetic retinopathy
Female
Follow-up studies
Humans
Intravitreal injections
Macular edema
Male
Middle aged
Retrospective studies
Time factors
Diffuse diabetic macular edema
Intravitreal bevacizumab
Panretinal photocoagulation
Proliferative diabetic retinopathy
Tractional retinal detachment
Vascular endothelial growth factor
monoclonal
optical coherence
Antibodies
Tomography

Rights

License

Abierto (Texto Completo)